202 related articles for article (PubMed ID: 12127117)
21. Advances in the Management of Gastric and Gastroesophageal Cancers.
Kamran SC; Hong TS; Wo JY
Curr Oncol Rep; 2016 Feb; 18(2):13. PubMed ID: 26769118
[TBL] [Abstract][Full Text] [Related]
22. Esophageal and esophagogastric junction cancers.
Ajani JA; Barthel JS; Bentrem DJ; D'Amico TA; Das P; Denlinger CS; Fuchs CS; Gerdes H; Glasgow RE; Hayman JA; Hofstetter WL; Ilson DH; Keswani RN; Kleinberg LR; Korn WM; Lockhart AC; Mulcahy MF; Orringer MB; Osarogiagbon RU; Posey JA; Sasson AR; Scott WJ; Shibata S; Strong VE; Varghese TK; Warren G; Washington MK; Willett C; Wright CD;
J Natl Compr Canc Netw; 2011 Aug; 9(8):830-87. PubMed ID: 21900218
[No Abstract] [Full Text] [Related]
23. The Management of Esophagogastric Cancers Enters a New Era.
Shah MA
Hematol Oncol Clin North Am; 2017 Jun; 31(3):xiii-xiv. PubMed ID: 28501094
[No Abstract] [Full Text] [Related]
24. Histopathologic classification of adenocarcinoma of the esophagogastric junction.
Baldus SE
Recent Results Cancer Res; 2010; 182():29-38. PubMed ID: 20676869
[No Abstract] [Full Text] [Related]
25. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation.
Taketa T; Correa AM; Suzuki A; Blum MA; Chien P; Lee JH; Welsh J; Lin SH; Maru DM; Erasmus JJ; Bhutani MS; Weston B; Rice DC; Vaporciyan AA; Hofstetter WL; Swisher SG; Ajani JA
Oncology; 2012; 83(5):300-4. PubMed ID: 22964903
[TBL] [Abstract][Full Text] [Related]
26. Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options.
Liakakos T; Katsios C; Roukos DH
Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):1-4. PubMed ID: 21309665
[No Abstract] [Full Text] [Related]
27. [Perioperative therapy in esophageal and stomach carcinoma].
Stahl M; Wilke H; Meyer HJ
Med Klin (Munich); 1996 Apr; 91 Suppl 3():85-92. PubMed ID: 8692126
[No Abstract] [Full Text] [Related]
28. Making It Stick: Management of Gastroesophageal Junction Adenocarcinoma with Poorly-Cohesive Cells (PCC).
Bouriez D; Gronnier C; Najah H; Collet D
Dig Dis Sci; 2022 Jun; 67(6):2005-2009. PubMed ID: 35430699
[No Abstract] [Full Text] [Related]
29. The impact of multimodality therapy of distal esophageal and gastroesophageal junction adenocarcinomas on treatment-related toxicity and complications.
Monjazeb AM; Blackstock AW
Semin Radiat Oncol; 2013 Jan; 23(1):60-73. PubMed ID: 23207048
[TBL] [Abstract][Full Text] [Related]
30. Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future.
Leichman L; Pendyala L; Leichman CG
Semin Oncol; 2003 Aug; 30(4 Suppl 11):11-8. PubMed ID: 14506599
[TBL] [Abstract][Full Text] [Related]
31. Siewert III Adenocarcinoma: Still Searching for the Right Treatment Combination.
Tang A; Sohal D; McNamara M; Murthy SC; Raja S
Surg Oncol Clin N Am; 2020 Oct; 29(4):647-653. PubMed ID: 32883464
[TBL] [Abstract][Full Text] [Related]
32. Oesophagogastric junction adenocarcinoma: which therapeutic approach?
Mariette C; Piessen G; Briez N; Gronnier C; Triboulet JP
Lancet Oncol; 2011 Mar; 12(3):296-305. PubMed ID: 21109491
[TBL] [Abstract][Full Text] [Related]
33. New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma: why bother?
Ajani JA
J Clin Oncol; 2007 Mar; 25(7):906-7; author reply 908-9. PubMed ID: 17327615
[No Abstract] [Full Text] [Related]
34. Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?
Cartwright E; Keane FK; Enzinger PC; Hong T; Chau I
Am Soc Clin Oncol Educ Book; 2018 May; 38():280-291. PubMed ID: 30231360
[TBL] [Abstract][Full Text] [Related]
35. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus.
Kleinberg L; Brock M; Gibson M
Curr Treat Options Oncol; 2015 Jul; 16(7):35. PubMed ID: 26112428
[TBL] [Abstract][Full Text] [Related]
36. Third international conference of the European Union Network of Excellence on gastric and esophagogastric junction cancer, Cologne, Germany, June 2012.
Moenig SP; Meyer HJ; Allum WH; De Manzoni G; Garofalo A; Baltin CT; Fetzner UK; Hoelscher AH
Gastric Cancer; 2015 Jan; 18(1):193-9. PubMed ID: 24522716
[TBL] [Abstract][Full Text] [Related]
37. Multimodality therapy of local regional esophageal cancer.
Kelsen DP
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S6-10. PubMed ID: 16399422
[TBL] [Abstract][Full Text] [Related]
38. [Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT].
Schröder W; Bruns CJ
Chirurg; 2019 Mar; 90(Suppl 2):27. PubMed ID: 30758590
[No Abstract] [Full Text] [Related]
39. Evidence-based review of the management of cancers of the gastroesophageal junction.
Narsule CK; Montgomery MM; Fernando HC
Thorac Surg Clin; 2012 Feb; 22(1):109-21, vii-viii. PubMed ID: 22108695
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction.
Lagarde SM; ten Kate FJ; Reitsma JB; Busch OR; van Lanschot JJ
J Clin Oncol; 2006 Sep; 24(26):4347-55. PubMed ID: 16963732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
